- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04383067
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase II single-center study of Tumor Infiltrating Lymphocytes (TIL) in urothelial carcinoma patients who failed at least one line of platinum based chemotherapy and one line of immunotherapy of targeted therapy.
Patients will undergo a baseline evaluation including imaging, blood and urine samples, EVG and physical examination to confirm suitability for the study.
Eligible patients will undergo surgery to collect a tumor sample for TIL culturing.
Patients will receive an autologus TIL infusion once the cells have been properly cultured.
Following the infusion, patients will receive a high dose of IL-2.
Following the intervention, patients will be monitored to evaluate study endpoints.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ronnie Shapira, MD.
- Phone Number: +972-3-5308414
- Email: Ronnie.Shapira@sheba.health.gov.il
Study Locations
-
-
-
Ramat Gan, Israel, 5262100
- Recruiting
- Sheba Medical Center
-
Contact:
- Ronnie Shapira, Dr
- Phone Number: 972-3-5308414
- Email: ronnie.shapira@sheba.health.gov.il
-
Contact:
- Meital Bar
- Phone Number: 972-3-5305201
- Email: meital.bar@sheba.healtnh.gov.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed Urothelial Carcinoma
- Progressed on first line platinum-based chemotherapy and on second line immunotherapy or targeted therapy (FGFR inhibitor)
- Measurable metastatic Urothelial Carcinoma with at least one lesion that is resectable for TIL generation.
- Patients with one or more brain metastases less than 1 cm each, and any patients with 1 or 2 brain metastases greater than 1 cm must have been treated and stable for 4 weeks.
- Greater than or equal to 18 years of age.
- Willing to practice birth control from the start of chemotherapy until 120 days after release from the hospital.
- Life expectancy of greater than three months
- Willing to sign a durable power of attorney
- Able to understand and sign the Informed Consent Document
- Clinical performance status of ECOG 0 or 1
Hematology:
- Absolute neutrophil count greater than 1000/mm3 without support of filgrastim
- Normal WBC ( > 3000/mm3).
- Hemoglobin greater than 8.0 g/dL
- Platelet count greater than 100,000/mm3
Serology:
- Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus can be less responsive to the experimental treatment and more susceptible to its toxicities.)
- Seronegative for Hepatitis B or Hepatitis C. (patients who recovered from previous infection and have no detected HBSAg or HCV RNA are allowed).
Chemistry:
- Serum ALT/AST less than three times the upper limit of normal (ULN).
- Serum creatinine less than or equal to 1.6 mg/dL
- Total bilirubin no more than x1.5 times the ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3 mg/dL.
- Negative pregnancy test in women of child bearing potential because of the potentially dangerous effects of the preparative chemotherapy on the fetus.
- More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients may have undergone minor surgical procedures with the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.
Exclusion Criteria:
- Upper tract Urothelial Carcinoma
- History of nephrectomy
- Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the non-myeloablative, lymphodepleting induction regimen on the fetus or infant.
- Systemic steroid therapy required (patients that require replacement therapy for adrenal insufficiency may be enrolled if steroid treatment dose do not exceed 10 mg of prednisone or equivalent).
- Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).
- Opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)
- History of severe immediate hypersensitivity reaction to any of the agents used in this study, including history of an anaphylactic reaction to penicillin or gentamicin
- History of coronary revascularization or ischemic heart disease.
- Any patient known to have an LVEF less than or equal to 50%.
- Documented LVEF of less than or equal to 50% tested in patients with clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block
- Documented FEV1 and DLCO (relative to predicted) less than or equal to 60%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tumor Infiltrating Lymphocytes (TIL)
|
Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation.
Patient will undergo surgery to remove either the primary tumor or a tumor metastasis.
The cells collected in this surgey will be cultured and reintroduced to the patient.
Following the cell infusion, patient will receive a high-dose bolus of IL-2.
high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance.
A maximum of 10 doses will be administered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy endpoint Objective Tumor response according to RECICT 1.1
Time Frame: 3 Years
|
The primary efficacy endpoint is defined as at least a 20% clinical benefit expressed as the sum of CR+PR+SD (each of these parameters defined as persisting for at least for 12 weeks).
|
3 Years
|
Safety endpoint Assess Adverse Events using CTCAE V4.03 during treatment and FU
Time Frame: 3 Years
|
The primary safety endpoint of the study is to evaluate the overall toxicity profile of the ACT procedure, with an emphasis on the side effects of the reduced intensity, non-myeloablative, lymphodepleting induction regimen.
|
3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 3 Years
|
Overall Survival (OS) according to RECICT 1.1
|
3 Years
|
Progression-Free Survival
Time Frame: 3 Years
|
Progression-Free Survival (PFS) according to RECICT 1.1
|
3 Years
|
Quality of Life (QoL) Assessment
Time Frame: 3 Years
|
Assessment of QoL using disease specific modules of the EORTC QLQ-C30 (version 3.0)
|
3 Years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tissue markers assessment
Time Frame: 3 Years
|
Tissue markers such as protein expression
|
3 Years
|
Blood Bio-markers assessment
Time Frame: 3 Years
|
Blood Bio-markers, including Circulating factors and peripheral blood mononuclear cell phenotype and function
|
3 Years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-19-6407-RS-TIL TCC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditionsUnited States, Puerto Rico
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditionsUnited States
-
Shanghai Miracogen Inc.RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial CancerChina
-
Incyte CorporationTerminatedMetastatic Urothelial Carcinoma | Unresectable Urothelial CarcinomaSpain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Clinical Trials on Tumor Infiltrating Lymphocytes (TIL)
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Shanghai Juncell TherapeuticsNot yet recruitingBreast Cancer | Gynecologic Cancer | Lung Cancer | Solid Tumor | Gastrointestinal Cancer
-
Saint John's Cancer InstituteTerminatedMetastatic MelanomaUnited States
-
Shanghai 10th People's HospitalShanghai Juncell TherapeuticsRecruiting
-
Yale UniversityIovance Biotherapeutics, Inc.CompletedMetastatic Triple Negative Breast CancerUnited States
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingBreast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of ImmunotherapyChina
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Udai KammulaRecruitingUveal Neoplasms | Melanoma, UvealUnited States
-
Iovance Biotherapeutics, Inc.CompletedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Sun Yat-sen UniversityUnknownNasopharyngeal Carcinoma | Hepatocellular Carcinoma | Breast CarcinomaChina